Attovia's ATTO-1310 Shows Clinical Proof of Concept; Cash Runway Extended to 2030
ATTO sits 43% above its 52-week low of $16.15 on light trading volume (0.2× avg).
Summary
Attovia reported Q2 2026 results with preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. A single dose produced rapid, deep itch relief and consistent lesion control, validating the ATTOBODY platform. Complete Phase 1b data are expected in Q4 2026, with two Phase 2 studies planned for 1H 2027. The upsized IPO raised $332.4 million gross, extending cash runway into 2030. This follows recent insider buying by Frazier Life Sciences and Director Colin Walsh, signaling confidence. The stock trades near its 52-week high, reflecting positive sentiment.
At the time of this announcement, ATTO was trading at $23.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $16.15 to $24.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.